News

Article

Glaucoma Research Foundation announces $2.5 million in grants to cure glaucoma

Author(s):

According to the foundation, the grants were awarded to 18 investigators at prominent universities in the United States, Nigeria, and Hong Kong.

(Image Credit: AdobeStock/Siam)

(Image Credit: AdobeStock/Siam)

The Glaucoma Research Foundation (GRF) announced a total of $2.5 million in annual research grants to support innovative research to cure glaucoma and restore vision.

According to a news release, the grants were awarded to 18 investigators at prominent universities in the United States, Nigeria, and Hong Kong.

Thomas M. Brunner, GRF president and CEO, pointed out that it is the largest annual research budget in GRF’s 46-year history.

“It's the first time we've had two Catalyst for a Cure initiatives running concurrently plus the greatest number of Shaffer Research Grants we have funded in a single year,” Brunner added. "The Vision Restoration Initiative and the Initiative to Prevent and Cure Neurodegeneration are making new discoveries bringing us closer to a cure for glaucoma."

GRF will award $1 million to the Catalyst for a Cure Vision Restoration Initiative principal investigators to continue their promising research toward restoring vision in glaucoma, and $800,000 to the Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration.

According to the news release, 10 1-year, $55,000 Shaffer Grants will be awarded to support research into glaucoma genetics and new treatment for glaucoma.

"In August we'll bring together scientists we fund with some of the brightest scientific minds in vision research for our annual Catalyst Meeting in Boston," Andrew G. Iwach, MD, GRF Board chairman, said in the news release "GRF is doing our best to invest in research that brings us closer to our goal of curing glaucoma and restoring vision, while at the same time developing better solutions for patients today."

Catalyst for a Cure Research Collaboration

Principal investigators: Xin Duan, PhD, UC San Francisco; Yang Hu, MD, PhD, Stanford; Anna La Torre, PhD, UC Davis; and Derek Welsbie, MD, PhD, UC San Diego; Sandro Da Mesquita, PhD, Mayo Clinic; Milica Margeta, MD, PhD, Mass Eye and Ear; Karthik Shekhar, PhD, UC Berkeley; and Humsa Venkatesh, PhD, Harvard.

The 2024 Shaffer Grants for Innovative Glaucoma Research:

  • Revathi Balasubramanian, PhD
    Columbia University
  • Kevin Chan, PhD
    New York University
  • Bryce Chiang, MD, PhD
    Stanford University
  • Cátia Gomes, PhD
    Indiana University
  • Meredith Gregory-Ksander, PhD
    Mass Eye and Ear, Harvard
  • Takaaki Kuwajima, PhD
    University of Pittsburgh
  • Margaret MacNeil, PhD
    York College, CUNY
  • Felipe Medeiros, MD, PhD
    Bascom Palmer Eye Institute
  • Olusola Olawoye, MD, PhD
    University of Ibadan
  • Samantha Sze Wan Shan, PhD
    Hong Kong Polytechnic University

By 2040, it is predicted that 111 million people around the world will have glaucoma.2

The Glaucoma Research Foundation is a national non-profit organization dedicated to finding a cure for glaucoma. Founded in 1978 in San Francisco, it continues to fund glaucoma research worldwide and empower a global community affected by the second leading cause of blindness.2

Reference:
  1. Foundation GR. Glaucoma Research Foundation Announces $2.5 Million in Grants to Cure Glaucoma. www.prnewswire.com. Accessed March 14, 2024. https://www.prnewswire.com/news-releases/glaucoma-research-foundation-announces-2-5-million-in-grants-to-cure-glaucoma-302088889.html
  2. ‌About Us - Glaucoma Research Foundation. Accessed March 14, 2024. https://glaucoma.org/about-us
Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
© 2024 MJH Life Sciences

All rights reserved.